PRV-LAV intravenous treatment alone significantly inhibited tumor growth, and combination with anti-mouse PD1 antibody also exhibited a synergistic effect, extending survival of the mice with tumors (Fig. 7F-H). The gene discussed is PDCD1; the disease is neoplasm.